Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients

Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA). OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS). MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA. Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity. This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.

NCT Number	NCT06466850
Lead Sponsor	Isfahan University of Medical Sciences
Conditions	Osteoarthritis, Knee
Enrollment	20 participants
Start Date	2024-01-01
Primary Completion	2026-12-25 (estimated)
Study Completion	2026-12-25 (estimated)
Updated on ClinicalTrials.gov	2025-09-15